Issues surrounding US Pharmaceutical supply chain. Issues surrounding the generic drug and biosimilar user free agreements. Issues surrounding the regulation of complex generic drugs. Issues related to Inflation Reduction Act.
2025 · 4th Quarter (Oct 1 - Dec 31)
TEVA PHARMACEUTICALS USA
Filed by CAPITOL HILL CONSULTING GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- CAPITOL HILL CONSULTING GROUP
- Client
- TEVA PHARMACEUTICALS USA
- Filing UUID
- 895b4d6d-6248-4b58-bb45-224f4a8292bc
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues surrounding Medicare reimbursement of generic drugs and biosimilars. Issues relating to the impact of prescription drug negotiation on generic drugs. Issues related to drug shortages. Issues related to drug pricing including drug negotiation.
Issues related to potential tariffs on generic drugs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.